- Home
- ISPR vs HURA Comparison
ISPR vs HURA Comparison
Compare ISPR & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ISPR | HURA |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.5M | 131.8M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ISPR | HURA |
|---|---|---|
| Price | $2.89 | $0.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.50 | ★ $11.50 |
| AVG Volume (30 Days) | 49.5K | ★ 551.9K |
| Earning Date | 02-09-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $118,506,875.00 | N/A |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | $40.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.44 | $0.80 |
| 52 Week High | $6.13 | $5.50 |
Technical Indicators
Market Signals| Indicator | ISPR | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 66.78 | 22.64 |
| Support Level | $2.37 | $0.81 |
| Resistance Level | $2.97 | $1.07 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | 0.05 | -0.06 |
| Stochastic Oscillator | 95.74 | 1.22 |
Price Performance
Historical ComparisonAbout ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.